FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivoDaniel Cejka(Medical University of Vienna), Volker Wacheck(Medical University of Vienna)British Journal of CancerMay 12, 200910.1038/sj.bjc.6605076Cited by 39SaveCiteExport RISWatch citationsRelated PapersDose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics|Cancer Management and Research|2011|5